Insights Into Chronic Lymphocytic Leukemia (CLL)

Perspectives of community physicians on the treatment of CLL

Southwest – March 22, 2022

Faculty Chair

Deborah Stephens, MD

University of Utah Health

Central – March 28, 2022

Faculty Chair

Marc Hoffmann, MD

University of Kansas Medical Center

Southeast – April 21, 2022

Faculty Chair

Deborah Stephens, MD

University of Utah Health

Puerto Rico – June 25, 2022

Faculty Chair

John Allan, MD

Weill Cornell Medicine

Northeast – August 19, 2022

Faculty Chair

Nicole Lamanna, MD

Columbia University Irving Medical Center

Midwest – September 17, 2022

Faculty Chair

Seema Bhat, MD

The Ohio State University Comprehensive Cancer Center

Northwest – November 18, 2022

Faculty Chair

Nadia Khan, MD

Northwestern Medicine

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Virtual series
  • Puerto Rico

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Chicago, IL
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of CLL
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, and BR

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.